肿瘤细胞治疗研究
英文原题：αβ and γδ T-cell responses to Epstein-Barr Virus: insights in immunocompetence, immune failure and therapeutic augmentation in transplant patients.
EBV是一种人类γ疱疹病毒，可在免疫功能正常（单核细胞增多症、慢性疲劳综合征、胃癌、地方性Burkitt淋巴瘤、头颈部癌）和免疫抑制（移植后淋巴增殖性疾病、EBV相关软组织肿瘤）患者中引起多种疾病。
Epstein-Barr病毒（EBV）是一种人类γ疱疹病毒，可在免疫功能正常（单核细胞增多症、慢性疲劳综合征、胃癌、地方性Burkitt淋巴瘤、头颈部癌）和免疫抑制（移植后淋巴增殖性疾病、EBV相关软组织肿瘤）患者中引起多种疾病。它引发复杂的体液和细胞免疫应答，包括固有免疫和适应性免疫成分。近年来，在理解EBV相关疾病中免疫细胞相互作用方面取得了实质性进展，并且已开发出几种治疗方法来增强针对EBV的细胞免疫，以控制EBV相关恶性肿瘤。本综述将聚焦于免疫抑制移植受者的最新进展。
Epstein-Barr Virus (EBV) is a human gamma herpes virus, which causes several diseases in immunocompetent (mononucleosis, chronic fatigue syndrome, gastric cancer, endemic Burkitt's lymphoma, head and neck cancer) and immunosuppressed (post-transplant lymphoproliferative disease, EBV-associated soft tissue tumors) patients. It elicits a complex humoral and cellular immune response with both innate and adaptive immune components. Substantial progress has been made in understanding the interplay of immune cells in EBV-associated diseases in recent years, and several therapeutic approaches have been developed to augment cellular immunity toward EBV for control of EBV-associated malignancy. This review will focus on recent developments in immunosuppressed transplant recipients.
MEMBER ACCOUNT
登录成功会直接打开下一页。
